Salignostics Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2016

Location

Jerusalem Israel

Primary Industry

Medical Devices & Equipment

About

Based in Israel, and founded in 2016 by co-founders Aaron Palmon, Omer Deutsch, Guy Krief, Raluca Cohen, and Yoav Neumann. Salignostics Ltd. operates as a medical company that develops saliva-based rapid diagnostics tests that detect a range of physiological conditions including Covid-19 and pregnancy. In April 2022, Salignostics raised USD 8 million in series A funding from individual and other investors. Salignostics Ltd. product offering includes SaliCov an antigen saliva test that detects the presence of COVID-19 in both symptomatic and asymptomatic patients; Salistick a rapid saliva-based pregnancy test for early pregnancy detection. The kit is based on technology that detects the pregnancy hormone ß-hCG in saliva. The company uses a lateral flow immunoassay platform to monitor health status, disease onset, progression, and treatment outcomes through non-invasive means. The company plans to use this series A funding to support its commercialization, development, and marketing efforts overseas and in Israel. The funding will also support the opening of a new plant in the Lavon Industrial Zone in Northern Israel.

Primary Industry

Medical Devices & Equipment

Sub Industries

Diagnostic Equipment, Medical Software

Website

www.salignostics.com

Verticals

HealthTech

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.